Anti-CD137 Monoclonal Antibody in Patients With Advanced Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability,
PK, and PD profiles of AGEN2373 as a monotherapy and in combination with Balstilimab
(AGEN2034), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid
tumors.